Showing 411-420 of 8235 results for "".
Taking Action: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/taking-action-quality-of-care-in-ad/19881/Beyond identifying barriers to AD patient care, the Quality of Care in Atopic Dermatitis initiative presents potential solutions. Eric Simpson, MD, MCR outlines some key strategies for improving care and emphasizes that some simple steps can make a big difference.Chemical Peels for Lip Augmentation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/chemical-peels-for-lip-augmentation--dcwokite/19585/For patients looking for natural results or who want an alternative to hyaluronic acid fillers and needles, deep chemical peels are an excellent alternative for lip augmentation, explains Kachiu Lee, MD. She shares treatment pearls and discusses the kind of results patients can expect.Antibiotics and the Mutant Selection Window
https://practicaldermatology.com/topics/atopic-dermatitis/antibiotics-and-the-mutant-protection-window/19537/When considering antibiotics for treating acne, Hilary Baldwin, MD says there's a new concept dermatologists should consider in preventing antibiotic resistance. She describes the mutant selection window and why a higher dose antibiotic may actually be safer and more effective.ASDS Survey: 8 Million Procedures in 2012
https://practicaldermatology.com/topics/practice-management/asds-survey-8-million-procedures-in-2012/19259/"More and more people are seeking care from dermatologic surgeons." ASDS President Timothy Flynn, MD addresses new findings about the public's dependence on dermatologic surgeons. Derm surgeons' expertise and training in cosmetic and medical care are discussed.How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workWhat Every Dermatologist Must Know About the History of Black Hair
https://practicaldermatology.com/topics/hair-nails/what-every-dermatologist-must-know-about-the-history-of-black-hair/23996/Knowledge of the historical, cultural, and social significance of hairstyles of Black patients may reduce implicit bias amongst dermatologists. In this article, Brooke Jackson, MD, FAAD, and Aliya Rodriguez, BS, explore the unique history and cultral impact of black hair.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis Bioteherapu